Cancer Partners of Nebraska offers unique access to clinical trials, thanks to our membership in two major National Cancer Institute (NCI) research networks: Alliance, as an MD Anderson Cancer Center affiliate, and ECOG-ACRIN Cancer Research Group.
If you are not able to resolve your concerns with the study doctor or study staff, if you have a complaint, or if you have general questions about what it means to be in a research study, you can call the Cancer Partners of Nebraska Human Research Protection Program at (402) 420-7000, Ext. 202, or email HumanProtections@cancerpartners.com.
Most clinical trials at Cancer Partners are interventional studies, meaning patients are assigned to a treatment or other intervention and their outcomes are measured. See the full list below sorted by type of cancer. If you wish to discuss a specific trial, please discuss it with your oncologist or contact our Research Department at (402) 327-7363.
A PHASE III CLINICAL TRIAL EVALUATING DEESCALATION OF BREAST RADIATION FOR CONSERVATIVE TREATMENT OF STAGE I, HORMONE SENSITIVE, HER2-NEGATIVE, ONCOTYPE RECURRENCE SCORE ≤ 18 BREAST CANCER
Learn MoreA Phase III Randomized Trial of Radiotherapy Optimization for Low-Risk HER2-Positive Breast Cancer (HERO*) *Her2 Radiation Optimization (HERO)
Learn MoreHigh Risk, HER2-Positive BC, T1-4, N0-3 w/residual disease post-op
Learn MoreA PHASE 3 RANDOMIZED, OPEN-LABEL STUDY OF OP-1250 MONOTHERAPY VS STANDARD OF CARE FOR THE TREATMENT OF ER+, HER2– ADVANCED OR METASTATIC BREAST CANCER FOLLOWING ENDOCRINE AND CDK 4/6 INHIBITOR THERAPY (OPERA-01)
A Phase II/III Randomized Study of R-MiniCHOP with or Without CC-486 (Oral Azacitidine) in Participants Age 75 Years or Older with Newly Diagnosed Diffuse Large B Cell Lymphoma, Grade IIIB Follicular Lymphoma, Transformed Lymphoma, and High-Grade B-Cell Lymphomas with MYC AND BCL2 and/or BCL6 Rearrangements
Learn MoreRandomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab Versus Delayed therapy with Venetoclax and Obinutzumab in Newly Diagnosed Asymptomatic High-Risk Patient with DLL/CLL: EVOLVE CLL/SLL Study.
Learn MoreA Randomized Phase 3 Trial for Newly Diagnosed Multiple Myeloma not Intended for Early Autologous Transplantation
COLON ADJUVANT CHEMOTHERAPY BASED ON EVALUATION OF RESIDUAL DISEASE (CIRCULATE-NORTH AMERICA)
Learn MoreRandomized Phase III Study of Combination AZD9291 (Osimertinib) and Bevacizumab Versus AZD9291 (Osimertinib) Alone as First-Line Treatment for Patients With Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)
Learn MoreStage II-III Resected NSCLC – Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Learn MoreIntegration of Immunotherapy into Adjuvant Therapy for Resected NSCLC: ALCHEMIST CHEMO-IO (ACCIO)
Learn MoreColon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-NORTH AMERICA)
Integration of Immunotherapy into Adjuvant Therapy for Resected NSCLC: ALCHEMIST CHEMO-IO (ACCIO)
Learn MoreA Randomized, Double-Blind, International Multicenter, Phase III Study to Evaluate the Anti-Tumor Efficacy and Safety of HLX10 (Recombinant Humanized Anti-PD-1 Monoclonal Antibody Injection) or Placebo in Combination with Chemotherapy (Carboplatin/Cisplatin-Etoposide) and Concurrent Radiotherapy in Patients with Limited-Stage Small Cell Lung Cancer (LS-SCLC)
Randomized Phase III Trial Incorporating Abiraterone Acetate with Prednisone and Apalutamide and Advanced Imaging into Salvage Treatment for Patients with Node-Positive Prostate Cancer after Radical Prostatectomy
Learn MoreA Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients with Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum
Phase II Randomized, Prospective Trial of Lutetium Lu 177 Dotatate PRRT Versus Capecitabine and Temozolomide in Well-Differentiated Pancreatic Neuroendocrine Tumors
MAPK Pathway Altered Malignancies – Expanded Ulixertinib (BVD-523) access in Patients with Advanced MAPK Pathway-Altered Malignancies.
The list of available biomarker studies is always changing. Please contact Cancer Partners Research Department for the most current list.
